InvestorsHub Logo
Followers 664
Posts 46911
Boards Moderated 2
Alias Born 03/30/2009

Re: None

Friday, 10/15/2021 10:50:23 AM

Friday, October 15, 2021 10:50:23 AM

Post# of 48316

OncoSec Medical (NASDAQ:ONCS), up 4.3% premarket was assumed with a Buy rating and $10 PT, which is more than 5-fold higher than last closing price.


BTIG analyst Kaveri Pohlman...assumed coverage of...Immuno-oncology companies, and believes "much of the most promising work" involves broader immune involvement in the anti-tumor battle either involving or in combination with less-systemically toxic therapeutic cytokines.


https://seekingalpha.com/news/3753129-btig-assumes-coverage-of-immuno-oncology-companies-oncosec-gains-on-buy-rating?utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+News+Smart

Don't know what this analyst sees in OncoSec. There hasn't even been a peep out of the new interim CEO since he took over.

$ONCS

Success is never final; failure is never fatal. It's courage that counts.--John Wooden (1910-2010)

Courage is being scared to death, but saddling up anyway.--John Wayne (1907-1979)